Selective serotonin re-uptake inhibitor use during pregnancy: Association with offspring birth size and gestational age

International Journal of Epidemiology

Volumn 45, Issue 1, 2016, Pages 170-177

  Viktorin, Alexander ^a   Lichtenstein, Paul ^a   Lundholm, Cecilia ^a   Almqvist, Catarina ^a,b   D'Onofrio, Brian M ^c   Larsson, Henrik ^a   Landén, Mikael ^a,d   Magnusson, Patrik K E ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Antidepressants; Depression; Medication; Pharmacoepidemiology; Pregnancy

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

AGE STRUCTURE; BIRTH RATE; CONFIDENCE INTERVAL; DRUG; EPIDEMIOLOGY; INHIBITOR; MEDICAL GEOGRAPHY; PREGNANCY; RESEARCH WORK;

ARTICLE; BIRTH WEIGHT; BODY SIZE; CHILD; COHORT ANALYSIS; DRUG EFFECT; GESTATIONAL AGE; HEAD CIRCUMFERENCE; HUMAN; NEWBORN; OFFSPRING BIRTH SIZE; OUTCOME ASSESSMENT; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PUERPERAL DEPRESSION; SIDE EFFECT; SWEDISH CITIZEN; ADULT; CHEMICALLY INDUCED; DEPRESSION; FEMALE; MALE; PREGNANCY; PREMATURE BIRTH; PRENATAL EXPOSURE; REGISTER; STATISTICAL MODEL; SWEDEN; YOUNG ADULT;

SWEDEN;

ADULT; BIRTH WEIGHT; COHORT STUDIES; DEPRESSION; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; LOGISTIC MODELS; MALE; PREGNANCY; PREMATURE BIRTH; PRENATAL EXPOSURE DELAYED EFFECTS; REGISTRIES; SEROTONIN UPTAKE INHIBITORS; SWEDEN; YOUNG ADULT;

EID: 84964068137     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyv351     Document Type: Article

References (37)

1. American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders(DSM-5 VR ). Arlington, VA: APA, 2013.
2. Murray CJ, Lopez AD. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science 1996;274:740-43.
3. Lecrubier Y. The burden of depression and anxiety in general medicine. J Clin Psychiatry 2001;62(Suppl 8):4-9;discussion 10-11.
4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
5. Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 2005;106:1071-83.
6. Meltzer-Brody S, Stuebe A. The long-term psychiatric and medical prognosis of perinatal mental illness. Best Pract Res Clin Obstet Gynaecol 2014;28:49-60.
7. Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Arch Women Ment Health 2005;8:77-87.
8. O'Hara MW, McCabe JE. Postpartum depression: current status and future directions. Annu Rev Clin Psychol 2013;9:379-407.
9. Flynn HA, Davis M, Marcus SM, Cunningham R, Blow FC. Rates of maternal depression in pediatric emergency department and relationship to child service utilization. Gen Hosp Psychiatry 2004;26:316-22.
10. Marmorstein NR, Malone SM, Iacono WG. Psychiatric disorders among offspring of depressed mothers: associations with paternal psychopathology. Am J Psychiatry 2004;161:1588-94.
11. Bernstein IH, Rush AJ, Yonkers K et al. Symptom features of postpartum depression: are they distinct? Depress Anxiety 2008;25:20-26.
12. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009;66:848-56.
13. Bakker MK, Kolling P, van den Berg PB, de Walle HE, de Jong van den Berg LT. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from theNetherlands. Br J Clin Pharmacol 2008;65:600_06.
14. Andrade SE, Raebel MA, Brown J et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 2008;198:194 e1-5.
15. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58.
16. Rayburn WF, Gonzalez CL, Christensen HD, Kupiec TC, Jacobsen JA, Stewart JD. Effect of antenatal exposure to paroxetine (paxil) on growth and physical maturation of mice offspring. J Matern Fetal Med 2000;9:136-41.
17. Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 2003;4:1002-12.
18. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medications. Am J Psychiatry 2003;160:993-96.
19. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009;163:949-54.
20. Wisner KL, Sit DK, Hanusa BH et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009;166:557-66.
21. Wen SW, Yang Q, Garner P et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006;194:961-66.
22. Kallen B, Olausson PO. Maternal use of selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008;17:801-06.
23. Kieler H, Artama M, Engeland A et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012;344:d8012.
24. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569.
25. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006;63:898-906.
26. Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Norgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010;2:29-36.
27. El Marroun H, Jaddoe VW, Hudziak JJ et al. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psychiatry 2012;69:706-14.
28. Lyell DJ, Chambers AS, Steidtmann D et al. Antenatal identification of major depressive disorder: a cohort study. Am J Obstet Gynecol 2012;207:506 e1-6.
29. Macklin R. Enrolling pregnant women in biomedical research. Lancet 2010;375:632-33.
30. D'Onofrio BM, Lahey BB, Turkheimer E, Lichtenstein P. Critical need for family-based, quasi-experimental designs in integrating genetic and social science research. Am J Public Health 2013;103(Suppl 1):S46-55.
31. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009;24:659-67.
32. Cnattingius S, Ericson A, Gunnarskog J, Kallen B. A quality study of a medical birth registry. Scand J Soc Med 1990;18:143-48.
33. Ekbom A. The Swedish Multi-generation Register. Methods Mol Biol 2011;675:215-20.
34. Wettermark B, Hammar N, Fored CM et al. The new Swedish Prescribed Drug Register - opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726-35.
35. Ludvigsson JF, Andersson E, Ekbom A et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:450.
36. Marsal K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr 1996;85:843-48.
37. Frisell T, Oberg S, Kuja-Halkola R, Sjolander A. Sibling comparison designs: bias from non-shared confounders and measurement error. Epidemiology 2012;23:713-20.